Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D
_256_384.jpg){kind=logo}
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
Heart failure affects an estimated 64.3 million people worldwide
WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The approval is supported by data from three pivotal clinical trials
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Subscribe To Our Newsletter & Stay Updated
